8 days ago
Kim Kardashian is dealing with a health issue that "really hits home."
During the Thursday, October 29, episode of The Kardashians, the 46-year-old reality star revealed that she needs surgery to address "irregularities" in her esophagus following her esophagitis diagnosis.
"So I've seen a couple of doctors, and it's been heavy on my mind lately," Kim said in the confessional, according to People. "I haven't really told too many people about this, just because I think it's something that really hits home for me and I just don't really wanna go there."
Kim's father, Robert Kardashian, died of esophageal cancer in 2003 at the age of 59.
"With my dad having passed away from esophagus cancer, hopefully I can just take medication and this will go away," Kim continued.
#really #esophagus #thursday
During the Thursday, October 29, episode of The Kardashians, the 46-year-old reality star revealed that she needs surgery to address "irregularities" in her esophagus following her esophagitis diagnosis.
"So I've seen a couple of doctors, and it's been heavy on my mind lately," Kim said in the confessional, according to People. "I haven't really told too many people about this, just because I think it's something that really hits home for me and I just don't really wanna go there."
Kim's father, Robert Kardashian, died of esophageal cancer in 2003 at the age of 59.
"With my dad having passed away from esophagus cancer, hopefully I can just take medication and this will go away," Kim continued.
#really #esophagus #thursday
11 days ago
McALLEN, Texas (AP) — The Ford Expedition rumbled to a stop and Cindy Banda's bedazzled flip-flops landed on the asphalt of the Houston cancer center's vast parking lot. She threaded through the rows of cars, a tally of patients who gather here to sit with chemotherapy needles or lie on radiation machines.
The elevator dinged open. A year ago in this building, surgeons removed Banda's right breast, and she still didn't know whether treatment had expunged the cancer from her body. Doctors had told her it would be tough to beat.
"I'm more of a positive person myself," Banda said, now sitting with a white wristband in a dim waiting room. But the bills are harder to dismiss, and the single mother with six children in her care repeated something like a mantra. "Keep the house. Keep the cars. And just keep the kids stable."
That's true for many Americans, as rising healthcare costs leave more families with a sinking feeling after seeing the bill for surgery or medication. Heading into the Nov. 3 midterm elections, about half of registered voters said healthcare costs are a major problem for them and their families, up from a little more than one-third four years ago, according to a Fox News poll from September.
With party control of Congress at stake, registered voters are nearly twice as likely to say they trust Democrats over Republicans to handle healthcare, according to an ******* ociated Press-NORC Center for Public Affairs Research poll from the same month. Those frustrations, combined with broader concerns over rising prices, have sapped support for President Donald Trump and his Republican Party.
#keep #cancer #rising #families
The elevator dinged open. A year ago in this building, surgeons removed Banda's right breast, and she still didn't know whether treatment had expunged the cancer from her body. Doctors had told her it would be tough to beat.
"I'm more of a positive person myself," Banda said, now sitting with a white wristband in a dim waiting room. But the bills are harder to dismiss, and the single mother with six children in her care repeated something like a mantra. "Keep the house. Keep the cars. And just keep the kids stable."
That's true for many Americans, as rising healthcare costs leave more families with a sinking feeling after seeing the bill for surgery or medication. Heading into the Nov. 3 midterm elections, about half of registered voters said healthcare costs are a major problem for them and their families, up from a little more than one-third four years ago, according to a Fox News poll from September.
With party control of Congress at stake, registered voters are nearly twice as likely to say they trust Democrats over Republicans to handle healthcare, according to an ******* ociated Press-NORC Center for Public Affairs Research poll from the same month. Those frustrations, combined with broader concerns over rising prices, have sapped support for President Donald Trump and his Republican Party.
#keep #cancer #rising #families
29 days ago
Pfizer (NYSE: PFE) is offering a dividend yield of roughly 6% today. That is well above the roughly 1% yield on offer from the S&P 500 index (SNPINDEX: ^GSPC) and the 1.4% average yield of pharmaceutical stocks. There are good reasons for the negative view of Pfizer, but investors may be ignoring the company's over 100-year history of success. Here's why you may want to consider buying this out-of-favor dividend stock while others are fearful.
Pfizer's stock rocketed higher during the coronavirus pandemic, as investors myopically focused on the company's COVID vaccine. When COVID turned out to be a less serious long-term threat than originally believed, Wall Street dumped Pfizer. At this point, the stock is down more than 50% from its 2021 high. That is a big part of the story behind the high yield.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
However, there's another piece that is more fundamental to the pharmaceutical industry. Like all drug makers, Pfizer's drugs receive time-limited patent protections. When patents expire, generic versions of the medications can be produced. That generally leads to a dramatic decline in revenue from Pfizer's drugs. Right now, Pfizer is facing down some notable patent expirations. This is a completely normal dynamic in the pharmaceutical sector.
Patent expirations are why drug companies are always on the lookout for new drugs. The problem is that patent expirations follow a set schedule, but drug development does not. Pfizer's drug pipeline isn't producing major new drugs right now, and it looks like it may have to work through a period in which new drugs won't fully offset revenue lost to patent expirations. This isn't uncommon, either, but investors are likely focusing on the short term rather than the long term when it comes to Pfizer.
#patent #yield #drug #expirations
Pfizer's stock rocketed higher during the coronavirus pandemic, as investors myopically focused on the company's COVID vaccine. When COVID turned out to be a less serious long-term threat than originally believed, Wall Street dumped Pfizer. At this point, the stock is down more than 50% from its 2021 high. That is a big part of the story behind the high yield.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
However, there's another piece that is more fundamental to the pharmaceutical industry. Like all drug makers, Pfizer's drugs receive time-limited patent protections. When patents expire, generic versions of the medications can be produced. That generally leads to a dramatic decline in revenue from Pfizer's drugs. Right now, Pfizer is facing down some notable patent expirations. This is a completely normal dynamic in the pharmaceutical sector.
Patent expirations are why drug companies are always on the lookout for new drugs. The problem is that patent expirations follow a set schedule, but drug development does not. Pfizer's drug pipeline isn't producing major new drugs right now, and it looks like it may have to work through a period in which new drugs won't fully offset revenue lost to patent expirations. This isn't uncommon, either, but investors are likely focusing on the short term rather than the long term when it comes to Pfizer.
#patent #yield #drug #expirations
30 days ago
"Rocky" franchise star Dolph Lundgren was considering ending his life after a years-long battle with kidney cancer. Then a doctor "saved" his life by discovering a misdiagnosis had led to ineffective treatment.
The Swedish action star, 68, revealed in 2023 that he had been diagnosed with cancer eight years prior and that he'd been given a few years left to live after finding it had metastasized to other parts of his body. However, a review by another doctor's team led to the revelation that his cells showed a mutation commonly found in lung cancer patients.
Now, with his memoir, "Fights Worth Fighting: Finding Strength in Struggle," recently published and a documentary, "Dolph: Unbreakable," due for digital release, he is opening up about the highs and lows he's experienced since his 2015 diagnosis.
In a Us Weekly interview published Oct. 6, "The Expendables" actor explained that obtaining a second opinion "saved my life," adding that "I wouldn't have been sitting here right now" if his oncologist, Dr. Alexandra Drakaki, had not caught his misdiagnosis.
When he switched to a new medication, he felt "relief that it started working quite quickly."
#star
The Swedish action star, 68, revealed in 2023 that he had been diagnosed with cancer eight years prior and that he'd been given a few years left to live after finding it had metastasized to other parts of his body. However, a review by another doctor's team led to the revelation that his cells showed a mutation commonly found in lung cancer patients.
Now, with his memoir, "Fights Worth Fighting: Finding Strength in Struggle," recently published and a documentary, "Dolph: Unbreakable," due for digital release, he is opening up about the highs and lows he's experienced since his 2015 diagnosis.
In a Us Weekly interview published Oct. 6, "The Expendables" actor explained that obtaining a second opinion "saved my life," adding that "I wouldn't have been sitting here right now" if his oncologist, Dr. Alexandra Drakaki, had not caught his misdiagnosis.
When he switched to a new medication, he felt "relief that it started working quite quickly."
#star
1 month ago
Marc Summers has lived with chronic lymphocytic leukemia for 15 years and takes daily medication after chemotherapy stopped working
The 75-year-old still enjoys long walks and recently logged 13 miles in one day
Summers is celebrating Double Dare's 40th anniversary and says he's lucky to do what he loves, and to be alive and healthy
Former Double Dare and Unwrapped host Marc Summers says he's more than lucky to be alive after cheating death not once, but twice.
In 2010, Summers was diagnosed with chronic lymphocytic leukemia, which he tells PEOPLE he's managed for 15 years.
#chronic
The 75-year-old still enjoys long walks and recently logged 13 miles in one day
Summers is celebrating Double Dare's 40th anniversary and says he's lucky to do what he loves, and to be alive and healthy
Former Double Dare and Unwrapped host Marc Summers says he's more than lucky to be alive after cheating death not once, but twice.
In 2010, Summers was diagnosed with chronic lymphocytic leukemia, which he tells PEOPLE he's managed for 15 years.
#chronic
1 month ago
Jenny Slatten's ALS battle has reached a heartbreaking new stage, with the beloved 90 Day Fiancé star now so weak that speaking has become painful—and her husband, Sumit Singh, has become her voice.
According to Page Six, the latest update came through a GoFundMe created to help cover Slatten's medical care in India, where Singh is caring for her full-time. According to Slatten's friend Penny, the 68-year-old reality star is "getting weaker by the day" while taking Edaravone and Riluzole, two medications intended to slow the progression of ALS. Penny said Slatten is also taking B12, melatonin and magnesium, but the treatments have left her drained.
"Jenny is getting weaker by the day," Penny wrote, adding that Slatten now "hardly speaks" because it hurts too much.
COMPLEX SHOP: Shop the brands you love, anytime and anywhere. Uncover what's next. Buy. Collect. Obsess.
"Sumit speaks more for her and is the main spokesperson for his wife," she continued. "Sumit is Jenny's main caregiver and doing a great job each day."
#sumit #shop
According to Page Six, the latest update came through a GoFundMe created to help cover Slatten's medical care in India, where Singh is caring for her full-time. According to Slatten's friend Penny, the 68-year-old reality star is "getting weaker by the day" while taking Edaravone and Riluzole, two medications intended to slow the progression of ALS. Penny said Slatten is also taking B12, melatonin and magnesium, but the treatments have left her drained.
"Jenny is getting weaker by the day," Penny wrote, adding that Slatten now "hardly speaks" because it hurts too much.
COMPLEX SHOP: Shop the brands you love, anytime and anywhere. Uncover what's next. Buy. Collect. Obsess.
"Sumit speaks more for her and is the main spokesperson for his wife," she continued. "Sumit is Jenny's main caregiver and doing a great job each day."
#sumit #shop
2 months ago
Definium Therapeutics, Inc. (NASDAQ:DFTX) has now delivered a third consecutive positive Phase 3 readout for its LSD-based medication, the second in generalized anxiety disorder. The result puts the company on a viable route toward a potential FDA approval of an LSD-based treatment for generalized anxiety disorder, and considering how closely psychedelic stocks have historically traded on each other's data, the reading carries far more weight than Definium's own ticker.
On September 14, Definium Therapeutics, Inc. (NASDAQ:DFTX) announced that its drug DT120, an orally disintegrating tablet formulation of LSD, was successful in Panorama, the company's second late-stage anxiety trial. Over 12 weeks, patients who received a 100-microgram dose experienced a 9.8-point decline on the Hamilton Anxiety Rating Scale, a typical clinical measure, compared to a 4.7-point drop with placebo.
The resulting 5.1-point placebo-adjusted improvement is similar to what the company's first pivotal anxiety trial, Voyage, showed back in August: an 11.6-point improvement versus 6.2 for placebo, a 5.4-point separation that Jefferies called one of the strongest placebo-adjusted efficacy results ever seen in generalized anxiety disorder, and that Stifel simply described as "a clean win."
Psychedelic equities have a history of trading as a group rather than as individual names, and this tendency applies both ways. In February 2026, when Compass Pathways, the sector's other clinical leader developing a psilocybin-based drug for treatment-resistant depression, reported positive late-stage data, shares of Definium Therapeutics, Inc. (NASDAQ:DFTX), Atai Beckley, GH Research, and Helus Pharma all rose, some by double digits.
That correlation is significant here because Definium's win is an independent validation of the broader therapeutic argument on which Compass and others are betting: a single dose of a classic psychedelic, administered in a controlled clinical setting, can produce lasting improvements in serious mental health conditions via pathways different from existing SSRIs and other standard-of-care drugs.
#definium #placebo
On September 14, Definium Therapeutics, Inc. (NASDAQ:DFTX) announced that its drug DT120, an orally disintegrating tablet formulation of LSD, was successful in Panorama, the company's second late-stage anxiety trial. Over 12 weeks, patients who received a 100-microgram dose experienced a 9.8-point decline on the Hamilton Anxiety Rating Scale, a typical clinical measure, compared to a 4.7-point drop with placebo.
The resulting 5.1-point placebo-adjusted improvement is similar to what the company's first pivotal anxiety trial, Voyage, showed back in August: an 11.6-point improvement versus 6.2 for placebo, a 5.4-point separation that Jefferies called one of the strongest placebo-adjusted efficacy results ever seen in generalized anxiety disorder, and that Stifel simply described as "a clean win."
Psychedelic equities have a history of trading as a group rather than as individual names, and this tendency applies both ways. In February 2026, when Compass Pathways, the sector's other clinical leader developing a psilocybin-based drug for treatment-resistant depression, reported positive late-stage data, shares of Definium Therapeutics, Inc. (NASDAQ:DFTX), Atai Beckley, GH Research, and Helus Pharma all rose, some by double digits.
That correlation is significant here because Definium's win is an independent validation of the broader therapeutic argument on which Compass and others are betting: a single dose of a classic psychedelic, administered in a controlled clinical setting, can produce lasting improvements in serious mental health conditions via pathways different from existing SSRIs and other standard-of-care drugs.
#definium #placebo
2 months ago
Without a signed, prospective contract, Medicaid treats family caregiver payments as gifts, exposing $60,000 in payments to a six-month nursing home ineligibility penalty.
A defensible care agreement must be signed before services begin, specify duties and market-rate pay, and be backed by time sheets and traceable payments.
At 20 documented hours per week, $2,500 monthly works out to roughly $29 per hour, defensible against the 2025 national median caregiver rate of $35.
Two retirees, same $1 million, same 4% rule, buy one finished with $1.4 million, the other hit $0 in 12 years. Our free reader guide explains the flaw that separated them, and the income-first method built to avoid it.
Picture a widow in her 80s who pays her adult daughter $2,500 a month for two years to handle bathing, meals, medications, driving to appointments, and overnight supervision. The care is real. The daughter cuts back her own job to provide it. One year later, mom breaks a hip, lands in a nursing home, and applies for institutional Medicaid. The caseworker pulls five years of bank statements, spots $60,000 in recurring payments to the daughter, and finds no signed agreement, no time sheets, no invoices. In that state, the agency treats every dollar as an uncompensated transfer, effectively a gift.
#signed #daughter
A defensible care agreement must be signed before services begin, specify duties and market-rate pay, and be backed by time sheets and traceable payments.
At 20 documented hours per week, $2,500 monthly works out to roughly $29 per hour, defensible against the 2025 national median caregiver rate of $35.
Two retirees, same $1 million, same 4% rule, buy one finished with $1.4 million, the other hit $0 in 12 years. Our free reader guide explains the flaw that separated them, and the income-first method built to avoid it.
Picture a widow in her 80s who pays her adult daughter $2,500 a month for two years to handle bathing, meals, medications, driving to appointments, and overnight supervision. The care is real. The daughter cuts back her own job to provide it. One year later, mom breaks a hip, lands in a nursing home, and applies for institutional Medicaid. The caseworker pulls five years of bank statements, spots $60,000 in recurring payments to the daughter, and finds no signed agreement, no time sheets, no invoices. In that state, the agency treats every dollar as an uncompensated transfer, effectively a gift.
#signed #daughter
2 months ago
Wolfe Research upgraded two prominent pharmaceutical companies to Outperform on August 13. The firm upgraded both Biogen Inc. (NASDAQ:BIIB) and AbbVie Inc. (NYSE:ABBV)'s ratings from Peer Perform, with Wolfe ***** igning them similar $300 price targets. The firm's logic in each case was based on a comparable set of factors: pipelines that the market appears to undervalue, and valuations that Wolfe believes are too low given each company's growth track.
Wolfe's thesis for Biogen Inc. (NASDAQ:BIIB) is mainly based on late-stage clinical programs, which it believes the stock has yet to reflect. The firm focused on two experimental therapies in particular, both of which have key late-stage clinical readouts expected over the coming year: litifilimab, which Wolfe believes could be the first biologic approved for cutaneous lupus erythematosus, and felzartamab, which the firm claims represents a bigger commercial opportunity in antibody-mediated transplant rejection than Wall Street currently thinks.
Wolfe also cited Biogen's acquisition of Apellis Pharmaceuticals as strengthening its near-term revenue base through the FDA-approved drugs Empaveli and Syfovre. That move is part of an overall pattern of Biogen Inc. (NASDAQ:BIIB) diversifying beyond its core neurology brand, with the company completing its acquisition of RayThera on August 6, adding another early-stage immunology platform to its pipeline.
Wolfe's Biogen Inc. (NASDAQ:BIIB) thesis is incomplete without valuation. The firm believes the stock is trading at a discount to the broader market, despite the company's development on Leqembi, its Alzheimer's medication, and what Wolfe described as solid commercial execution overall.
AbbVie's upgrade is based on a slightly different premise: patent strength and cash generation rather than simple clinical events. Wolfe stated that AbbVie's 2027 earnings multiple of 14.6x seemed too low for a company that forecasts high-single-digit revenue growth for the rest of the decade. AbbVie's patent position, according to Wolfe, sets the company apart from its competitors in a way that the market has yet to completely price in.
#wolfe #firm #market #clinical
Wolfe's thesis for Biogen Inc. (NASDAQ:BIIB) is mainly based on late-stage clinical programs, which it believes the stock has yet to reflect. The firm focused on two experimental therapies in particular, both of which have key late-stage clinical readouts expected over the coming year: litifilimab, which Wolfe believes could be the first biologic approved for cutaneous lupus erythematosus, and felzartamab, which the firm claims represents a bigger commercial opportunity in antibody-mediated transplant rejection than Wall Street currently thinks.
Wolfe also cited Biogen's acquisition of Apellis Pharmaceuticals as strengthening its near-term revenue base through the FDA-approved drugs Empaveli and Syfovre. That move is part of an overall pattern of Biogen Inc. (NASDAQ:BIIB) diversifying beyond its core neurology brand, with the company completing its acquisition of RayThera on August 6, adding another early-stage immunology platform to its pipeline.
Wolfe's Biogen Inc. (NASDAQ:BIIB) thesis is incomplete without valuation. The firm believes the stock is trading at a discount to the broader market, despite the company's development on Leqembi, its Alzheimer's medication, and what Wolfe described as solid commercial execution overall.
AbbVie's upgrade is based on a slightly different premise: patent strength and cash generation rather than simple clinical events. Wolfe stated that AbbVie's 2027 earnings multiple of 14.6x seemed too low for a company that forecasts high-single-digit revenue growth for the rest of the decade. AbbVie's patent position, according to Wolfe, sets the company apart from its competitors in a way that the market has yet to completely price in.
#wolfe #firm #market #clinical
2 months ago
A commonly used drug has been linked to a higher risk of death in a new study.
The antibiotic, cefepime, which is used to treat bacterial infections like pneumonia, UTIs and skin infections, is typically administered via injection by healthcare providers in a clinical setting.
Severe side effects may include confusion, decreased consciousness or seizures, especially in older patients and those with kidney problems, among many other common symptoms, according to Mayo Clinic.
Older Adults Taking 5 Or More Prescription Drugs Face Higher Risk Of Death, Study Finds
New research suggests the medication may be ****** ociated with a higher risk of all-cause mortality.
#risk
The antibiotic, cefepime, which is used to treat bacterial infections like pneumonia, UTIs and skin infections, is typically administered via injection by healthcare providers in a clinical setting.
Severe side effects may include confusion, decreased consciousness or seizures, especially in older patients and those with kidney problems, among many other common symptoms, according to Mayo Clinic.
Older Adults Taking 5 Or More Prescription Drugs Face Higher Risk Of Death, Study Finds
New research suggests the medication may be ****** ociated with a higher risk of all-cause mortality.
#risk
2 months ago
(NewsNation) — A new study found that a rare but serious brain condition has been identified in a small number of people taking popular weight-loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound.
Wernicke encephalopathy is a rare neurological disorder caused by a severe deficiency of vitamin B1, also known as thiamine.
GLP-1 prescriptions for kids up more than 30,000% since 2019
Researchers identified 15 cases reported in 2023 and 2024 among people taking GLP-1 medications containing semaglutide, found in Ozempic and Wegovy, or tirzepatide, found in Mounjaro and Zepbound.
Vitamin B1 is essential for proper nerve function. Without enough of it, patients can develop confusion, problems with balance and coordination, and abnormal eye movements.
#zepbound #vitamin #identified
Wernicke encephalopathy is a rare neurological disorder caused by a severe deficiency of vitamin B1, also known as thiamine.
GLP-1 prescriptions for kids up more than 30,000% since 2019
Researchers identified 15 cases reported in 2023 and 2024 among people taking GLP-1 medications containing semaglutide, found in Ozempic and Wegovy, or tirzepatide, found in Mounjaro and Zepbound.
Vitamin B1 is essential for proper nerve function. Without enough of it, patients can develop confusion, problems with balance and coordination, and abnormal eye movements.
#zepbound #vitamin #identified
2 months ago
CHRIS DELMAS / Getty Images
Novig / Via youtu.be
Novig / Via youtu.be
Related: "23 Celebs Who Have Admitted To Using Ozempic Or Other Weight Loss Medication"
sydneysweeney / Via instagram.com
#getty
Novig / Via youtu.be
Novig / Via youtu.be
Related: "23 Celebs Who Have Admitted To Using Ozempic Or Other Weight Loss Medication"
sydneysweeney / Via instagram.com
#getty
2 months ago
Investigators looking into Hayden Panettiere's death are reportedly focusing on a single pill they believe contained fentanyl.
Multiple law enforcement sources with direct knowledge of the investigation told TMZ that Panettiere took what she believed was oxycodone on the morning of Aug. 16, the day she died at age 36. Their working theory is that the pill had been laced with fentanyl.
The Greenville County Coroner's Office has not announced Panettiere's cause or manner of death, and toxicology results remain pending. TMZ's sources themselves cautioned that their theory still depends on those results.
The new report arrives as federal and local investigators try to determine where drugs and medications connected to Panettiere came from. The Los Angeles Times independently reported before TMZ's latest story that DEA agents and local authorities had been questioning people as part of that effort.
TMZ's sources allege that Panettiere had been obtaining black-market prescription drugs from a longtime source in Los Angeles before traveling to South Carolina on Aug. 15.
#panettiere #sources
Multiple law enforcement sources with direct knowledge of the investigation told TMZ that Panettiere took what she believed was oxycodone on the morning of Aug. 16, the day she died at age 36. Their working theory is that the pill had been laced with fentanyl.
The Greenville County Coroner's Office has not announced Panettiere's cause or manner of death, and toxicology results remain pending. TMZ's sources themselves cautioned that their theory still depends on those results.
The new report arrives as federal and local investigators try to determine where drugs and medications connected to Panettiere came from. The Los Angeles Times independently reported before TMZ's latest story that DEA agents and local authorities had been questioning people as part of that effort.
TMZ's sources allege that Panettiere had been obtaining black-market prescription drugs from a longtime source in Los Angeles before traveling to South Carolina on Aug. 15.
#panettiere #sources
2 months ago
Gareth Cattermole / Getty Images
©FX Networks/Courtesy Everett Collection
Ser Baffo / ©Hulu/Disney / Courtesy Everett Collection
Related: "23 Celebs Who Have Admitted To Using Ozempic Or Other Weight Loss Medication"
© Searchlight Pictures / Courtesy Everett Collection
#courtesy #everett #getty #networks
©FX Networks/Courtesy Everett Collection
Ser Baffo / ©Hulu/Disney / Courtesy Everett Collection
Related: "23 Celebs Who Have Admitted To Using Ozempic Or Other Weight Loss Medication"
© Searchlight Pictures / Courtesy Everett Collection
#courtesy #everett #getty #networks
2 months ago
On August 13, a federal appeals court ruled in favor of Gilead Sciences, Inc. (NASDAQ:GILD), upholding a preliminary injunction that bars the defendants from importing or facilitating the sale of foreign-market Gilead-branded medications in the US. The US Court of Appeals for the Fourth Circuit found that the differences between Gilead's HIV medication for the US market and the foreign versions being imported were "material, not theoretical." The controversy began in December 2024 when Gilead Sciences, Inc. (NASDAQ:GILD) filed suit against a number of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its best-selling HIV drug Biktarvy.
The dispute dates back to December 2024, when Gilead Sciences, Inc. (NASDAQ:GILD) sued a group of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its top-selling HIV drug Biktarvy. The lawsuit arose from a specific instance in which a patient in Maryland received the medicine in the mail from Turkey, with label instructions written in Turkish.
A federal district court in Baltimore ruled in Gilead's favor and ordered a preliminary injunction, determining that the company was likely to succeed on its Lanham Act trademark violation and unfair competition arguments. As the case continued, the injunction was increased to include new sellers like CanaRx, ElectRx, and ScriptSourcing. The defendants filed an appeal with the Fourth Circuit, and the district judge declined to suspend the injunction while the appeal was pending, thus the import restriction has been in effect the entire time. The recent ruling maintains the order rather than overturning it.
In court documents, Rx Valet stated that the Turkish-sourced Biktarvy was chemically identical to the US version, which was offered at a significantly higher price. Meritain, for its part, said that it has never supported getting non-FDA-approved pharmaceuticals from outside the US and denies the claims, despite being named as a defendant.
The Fourth Circuit rejected the defendants' main argument that the imported and domestic versions of Biktarvy are interchangeable. The court's judgment that the two versions differ materially, not just in packaging or labeling, but also in the quality-control protocols that each version goes through before reaching a patient, challenges the basic argument that these alternative funding programs have used to support their business model.
#gild
The dispute dates back to December 2024, when Gilead Sciences, Inc. (NASDAQ:GILD) sued a group of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its top-selling HIV drug Biktarvy. The lawsuit arose from a specific instance in which a patient in Maryland received the medicine in the mail from Turkey, with label instructions written in Turkish.
A federal district court in Baltimore ruled in Gilead's favor and ordered a preliminary injunction, determining that the company was likely to succeed on its Lanham Act trademark violation and unfair competition arguments. As the case continued, the injunction was increased to include new sellers like CanaRx, ElectRx, and ScriptSourcing. The defendants filed an appeal with the Fourth Circuit, and the district judge declined to suspend the injunction while the appeal was pending, thus the import restriction has been in effect the entire time. The recent ruling maintains the order rather than overturning it.
In court documents, Rx Valet stated that the Turkish-sourced Biktarvy was chemically identical to the US version, which was offered at a significantly higher price. Meritain, for its part, said that it has never supported getting non-FDA-approved pharmaceuticals from outside the US and denies the claims, despite being named as a defendant.
The Fourth Circuit rejected the defendants' main argument that the imported and domestic versions of Biktarvy are interchangeable. The court's judgment that the two versions differ materially, not just in packaging or labeling, but also in the quality-control protocols that each version goes through before reaching a patient, challenges the basic argument that these alternative funding programs have used to support their business model.
#gild
2 months ago
Warning: This post mentions rape, child ******* abuse, child abuse, murder, domestic violence, and gun violence.
Johnny Nunez / WireImage / Via Getty
Jason Armond / Los Angeles Times via Getty Images
Handout / California Department of Corrections via Getty Images
Related: "23 Celebs Who Have Admitted To Using Ozempic Or Other Weight Loss Medication"
#abuse
Johnny Nunez / WireImage / Via Getty
Jason Armond / Los Angeles Times via Getty Images
Handout / California Department of Corrections via Getty Images
Related: "23 Celebs Who Have Admitted To Using Ozempic Or Other Weight Loss Medication"
#abuse
2 months ago
This article mentions allegations of ******* ual ******* ault.
Anadolu / Getty Images
United Archives / Getty Images
Related: "23 Celebs Who Have Admitted To Using Ozempic Or Other Weight Loss Medication"
SCOTT FLYNN / Getty Images
#anadolu
Anadolu / Getty Images
United Archives / Getty Images
Related: "23 Celebs Who Have Admitted To Using Ozempic Or Other Weight Loss Medication"
SCOTT FLYNN / Getty Images
#anadolu
2 months ago
Amy Sussman / Getty Images, Icon Sportswire / Getty Images
Michael Buckner / Getty Images
Related: "23 Celebs Who Have Admitted To Using Ozempic Or Other Weight Loss Medication"
Shailene hasn't commented much on the relationship or the breakup, previously noting that talking about it "always" made her cry.
Meanwhile, Aaron publicly thanked Shailene for their time together in the wake of the split, while later apologizing to her for the backlash she faced over his divisive comments about the COVID-19 vaccine.
#getty #michael
Michael Buckner / Getty Images
Related: "23 Celebs Who Have Admitted To Using Ozempic Or Other Weight Loss Medication"
Shailene hasn't commented much on the relationship or the breakup, previously noting that talking about it "always" made her cry.
Meanwhile, Aaron publicly thanked Shailene for their time together in the wake of the split, while later apologizing to her for the backlash she faced over his divisive comments about the COVID-19 vaccine.
#getty #michael
2 months ago
Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
A health savings account (HSA) is a type of account that lets you save — and potentially invest — for healthcare expenses while earning tax benefits along the way. Depending on your financial situation and immediate medical needs, an HSA can even be a valuable retirement planning tool. But HSAs aren't available to everyone. Continue reading to learn how HSAs work, their rules, and pros and cons.
A health savings account is a tax-advantaged account you can use to pay for qualifying medical expenses, including prescription medications, eyeglasses, doctor's visits, and more. Some HSAs function like a savings account, while others give you the option to invest your funds for future use.
HSAs are known for their triple tax advantage: You fund them with pre-tax dollars, your contributions grow tax-free, and withdrawals are tax-free as long as you use them for qualifying medical expenses. For this reason, HSAs can be a valuable retirement savings tool if you don't need the funds to pay for immediate medical needs.
Unlike flexible spending accounts (FSAs), HSA contributions don't expire at the end of the year. This means you can contribute to your account year after year without the need to "use it or lose it." HSAs aren't subject to required minimum distributions, either.
#account #medical #year
A health savings account (HSA) is a type of account that lets you save — and potentially invest — for healthcare expenses while earning tax benefits along the way. Depending on your financial situation and immediate medical needs, an HSA can even be a valuable retirement planning tool. But HSAs aren't available to everyone. Continue reading to learn how HSAs work, their rules, and pros and cons.
A health savings account is a tax-advantaged account you can use to pay for qualifying medical expenses, including prescription medications, eyeglasses, doctor's visits, and more. Some HSAs function like a savings account, while others give you the option to invest your funds for future use.
HSAs are known for their triple tax advantage: You fund them with pre-tax dollars, your contributions grow tax-free, and withdrawals are tax-free as long as you use them for qualifying medical expenses. For this reason, HSAs can be a valuable retirement savings tool if you don't need the funds to pay for immediate medical needs.
Unlike flexible spending accounts (FSAs), HSA contributions don't expire at the end of the year. This means you can contribute to your account year after year without the need to "use it or lose it." HSAs aren't subject to required minimum distributions, either.
#account #medical #year
2 months ago
Our ***** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Management attributes the sequential improvement in comparable sales to enhanced digital conversion and the successful scaling of private brand franchises like THERMACHILL.
The company is navigating a structural shift in customer behavior driven by GLP-1 medication adoption, which has led to temporary pauses in apparel purchasing during weight loss journeys.
Performance was significantly bolstered by a $4.6 million IEEPA tariff refund, which masked a 70 basis point decline in underlying merchandise margins caused by higher markdowns and shipping surcharges.
Strategic focus has shifted toward 'Fit Authority' through the FITMAP initiative, which has scanned 150,000 customers and resulted in higher average order values and lower return rates.
#performance
Management attributes the sequential improvement in comparable sales to enhanced digital conversion and the successful scaling of private brand franchises like THERMACHILL.
The company is navigating a structural shift in customer behavior driven by GLP-1 medication adoption, which has led to temporary pauses in apparel purchasing during weight loss journeys.
Performance was significantly bolstered by a $4.6 million IEEPA tariff refund, which masked a 70 basis point decline in underlying merchandise margins caused by higher markdowns and shipping surcharges.
Strategic focus has shifted toward 'Fit Authority' through the FITMAP initiative, which has scanned 150,000 customers and resulted in higher average order values and lower return rates.
#performance
2 months ago
Back in August, Bayern Munich's Jamal Musiala collapsed on the pitch in consecutive matches only three days apart from each other. There was outside concern that his professional career might be over. He quickly attributed the issue to a change in medication for a known issue but his critics were far from convinced.
A short three weeks later, Musiala was back in the starting XI of a Champions League match. After Bodø/Glimt was forced to replace their goalkeeper at halftime, Musiala jumped on a loose ball and scored the eventual game winner.
Bayern’s 900th goal in European competition 👏 pic.twitter.com/AKNiTIBUkx
In the postgame interview (via iMiaSanMia), Vincent Kompany praised Musiala for his efforts.
"Everyone was happy for him, 75k people in the stadium and the people in front of their TVs," said Kompany. "We knew his moment would come. He scored a really important goal. It's great for Jamal, hopefully the focus now will only be on his performances. He knows how to deal with the other topic and will continue to get all support from us."
#musiala #back #three #ISSUE
A short three weeks later, Musiala was back in the starting XI of a Champions League match. After Bodø/Glimt was forced to replace their goalkeeper at halftime, Musiala jumped on a loose ball and scored the eventual game winner.
Bayern’s 900th goal in European competition 👏 pic.twitter.com/AKNiTIBUkx
In the postgame interview (via iMiaSanMia), Vincent Kompany praised Musiala for his efforts.
"Everyone was happy for him, 75k people in the stadium and the people in front of their TVs," said Kompany. "We knew his moment would come. He scored a really important goal. It's great for Jamal, hopefully the focus now will only be on his performances. He knows how to deal with the other topic and will continue to get all support from us."
#musiala #back #three #ISSUE
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
2 months ago
Impax ***** et Management, based in London and specializing in sustainable investing, released its Q2 2026 investor letter for the "Impax US Sustainable Economy Fund". The letter can be downloaded here. The US Sustainable Economy portfolio outperformed the Russell 1000 in Q2 2026, with Institutional Class at 17.96%, Investor Class at 17.95%, and Class A at 17.92%, versus the index's 15.14%. Sector allocation and stock selection drove performance. The sustainability tools, including the Impax Sustainability Lens and Corporate Resilience framework, contributed positively. Equity markets rallied, with both the S&P 500 and Nasdaq reaching new highs before retreating. A key trend was rotation into AI and tech stocks, supported by mega-cap earnings and data center investments (US$750bn to US$1tn). In the second half of 2026, markets may remain volatile amid debates on AI adoption pace and economic momentum. However, growth tied to energy security and efficiency remains compelling, with demand for power, grid, and resource-efficient solutions supporting companies that benefit. The team focuses on businesses with strong growth, sound management, and attractive valuations, adjusting holdings as needed. This approach aims to build well-diversified, differentiated portfolios. Also, please check the fund's top five holdings for its best picks in 2026.
In its second-quarter 2026 investor letter, Impax US Sustainable Economy Fund highlighted Zoetis Inc. (NYSE:ZTS). Zoetis Inc. (NYSE:ZTS), an animal health company focused on animal health medications, vaccines, and diagnostic products, detracted from the Fund's performance during the quarter. On September 04, 2026, Zoetis Inc. (NYSE:ZTS) closed at $75.81 per share. Over the past month, Zoetis Inc. (NYSE:ZTS) returned 1.31%, but its shares are down 50.04% over the past year. Zoetis Inc. (NYSE:ZTS) has a market capitalization of $31.33 billion.
Impax US Sustainable Economy Fund stated the following regarding Zoetis Inc. (NYSE:ZTS) in its Q2 2026 investor letter:
"Zoetis Inc. (NYSE:ZTS) (Pharmaceuticals, Health Care) is owned for its attractive sustainability opportunity profile in areas including Wellbeing and Evolving Health Care Challenge, as well as its strong governance profile. The stock declined sharply in the quarter following a downward revision to near-term earnings guidance. Sales of Librela, the company's key canine arthritis pain management product, continued to face headwinds from safety perception concerns among some veterinarians, and management indicated that the ramp-up of next-generation product launches would extend into the following year."
#economy #Health
In its second-quarter 2026 investor letter, Impax US Sustainable Economy Fund highlighted Zoetis Inc. (NYSE:ZTS). Zoetis Inc. (NYSE:ZTS), an animal health company focused on animal health medications, vaccines, and diagnostic products, detracted from the Fund's performance during the quarter. On September 04, 2026, Zoetis Inc. (NYSE:ZTS) closed at $75.81 per share. Over the past month, Zoetis Inc. (NYSE:ZTS) returned 1.31%, but its shares are down 50.04% over the past year. Zoetis Inc. (NYSE:ZTS) has a market capitalization of $31.33 billion.
Impax US Sustainable Economy Fund stated the following regarding Zoetis Inc. (NYSE:ZTS) in its Q2 2026 investor letter:
"Zoetis Inc. (NYSE:ZTS) (Pharmaceuticals, Health Care) is owned for its attractive sustainability opportunity profile in areas including Wellbeing and Evolving Health Care Challenge, as well as its strong governance profile. The stock declined sharply in the quarter following a downward revision to near-term earnings guidance. Sales of Librela, the company's key canine arthritis pain management product, continued to face headwinds from safety perception concerns among some veterinarians, and management indicated that the ramp-up of next-generation product launches would extend into the following year."
#economy #Health
2 months ago
Airing a Super Bowl is a bit like a presidential election.
It might come around every four years, but candidates – in this case, the four networks with the privilege and pockets to be in the broadcast rotation – are constantly jockeying and positioning themselves, especially as their turn nears.
That makes CBS' conundrum with Tony Romo even more precarious. Super Bowl 61 will return to ABC/ESPN for the first time in two decades to end the 2026 season on Feb. 14, 2027, but then CBS will officially be on the clock for February 2028, when it will host its first Super-Bowl broadcast since 2023.
Romo, the network's No. 1 game ****** yst who partners with Jim Nantz, was arrested on suspicion of operating a vehicle while intoxicated (OWI) and pleaded no contest Sept. 2 to three charges he faced from the incident, which occurred while in his native Wisconsin on July 23. The subsequent police officer bodycam footage became Internet fodder, as Romo failed his field sobriety test, told the officer who pulled him over he was "going to see grandma and grandpa" (his own parents) and had an open container in the passenger seat.
In his first public comment since the arrest, Romo said via a Sept. 1 statement posted to his Instagram account, "I own this completely." He also noted an over-reliance on alcohol stemming from a dependence on pain medication following his playing career.
#romo #super #sept
It might come around every four years, but candidates – in this case, the four networks with the privilege and pockets to be in the broadcast rotation – are constantly jockeying and positioning themselves, especially as their turn nears.
That makes CBS' conundrum with Tony Romo even more precarious. Super Bowl 61 will return to ABC/ESPN for the first time in two decades to end the 2026 season on Feb. 14, 2027, but then CBS will officially be on the clock for February 2028, when it will host its first Super-Bowl broadcast since 2023.
Romo, the network's No. 1 game ****** yst who partners with Jim Nantz, was arrested on suspicion of operating a vehicle while intoxicated (OWI) and pleaded no contest Sept. 2 to three charges he faced from the incident, which occurred while in his native Wisconsin on July 23. The subsequent police officer bodycam footage became Internet fodder, as Romo failed his field sobriety test, told the officer who pulled him over he was "going to see grandma and grandpa" (his own parents) and had an open container in the passenger seat.
In his first public comment since the arrest, Romo said via a Sept. 1 statement posted to his Instagram account, "I own this completely." He also noted an over-reliance on alcohol stemming from a dependence on pain medication following his playing career.
#romo #super #sept
2 months ago
Starting statin therapy shortly after a type 2 diabetes diagnosis may not only protect the heart — it may also be linked to a lower dementia risk.
A large study presented at the European Society of Cardiology Congress in Munich on Aug. 30 found that adults who began taking a statin within one year of their type 2 diabetes diagnosis had a 15% lower relative risk of developing dementia over 10 years compared to those who did not take the medication within five years.
Even for those who delayed starting a statin for one to five years, there was still a 10% lower relative risk, according to the findings, which were published in The Lancet Regional Health – Europe.
3 Things To Avoid In Middle Age Could Mean 13 More Years Without Dementia, Study Finds
A statin is a prescription medication that lowers "bad" LDL cholesterol and helps reduce the risk of heart attack and stroke.
#risk #lower #study #diagnosis
A large study presented at the European Society of Cardiology Congress in Munich on Aug. 30 found that adults who began taking a statin within one year of their type 2 diabetes diagnosis had a 15% lower relative risk of developing dementia over 10 years compared to those who did not take the medication within five years.
Even for those who delayed starting a statin for one to five years, there was still a 10% lower relative risk, according to the findings, which were published in The Lancet Regional Health – Europe.
3 Things To Avoid In Middle Age Could Mean 13 More Years Without Dementia, Study Finds
A statin is a prescription medication that lowers "bad" LDL cholesterol and helps reduce the risk of heart attack and stroke.
#risk #lower #study #diagnosis
2 months ago
Ro Khanna is a Democratic congressman from California whose stock picks keep making headlines. His latest financial disclosures show steady buying in two names through June and July.
Uber Technologies, Inc. (NYSE:UBER) shows up more than any other stock in the filing. Khanna's disclosures list several separate Uber purchases between June 15 and July 29, with no sales in that stretch. Uber is down about 18% over the past year.
Chewy Inc. (NYSE:CHWY) is the second name. The filing shows nine Chewy purchases between July 13 and July 30.
Chewy is down about 40% over the past year and 30% so far this year. Is this a potential opportunity to buy the stock on the dip? Let's **** yze.
Chewy, Inc. (NYSE:CHWY) sells pet food, treats, supplies and medications online. The business runs on Autoship, a subscription program where customers set up recurring deliveries.
#chewy #chwy #shows
Uber Technologies, Inc. (NYSE:UBER) shows up more than any other stock in the filing. Khanna's disclosures list several separate Uber purchases between June 15 and July 29, with no sales in that stretch. Uber is down about 18% over the past year.
Chewy Inc. (NYSE:CHWY) is the second name. The filing shows nine Chewy purchases between July 13 and July 30.
Chewy is down about 40% over the past year and 30% so far this year. Is this a potential opportunity to buy the stock on the dip? Let's **** yze.
Chewy, Inc. (NYSE:CHWY) sells pet food, treats, supplies and medications online. The business runs on Autoship, a subscription program where customers set up recurring deliveries.
#chewy #chwy #shows
2 months ago
Tony Romo recently pleaded no contest and accepted responsibility for his OWI arrest, but Ryan Leaf had one issue with his statement.
After pleading no contest to a civil offense of operating while intoxicated in Wisconsin, Romo put out a statement admitting his "over-reliance on alcohol" while taking full responsibility for his actions before teasing his return to CBS, a return the network has not commented on as their lead NFL ****** yst remains on indefinite leave. But Romo also attributed his "over-reliance on alcohol" to his attempt at getting off a dependence on paid medication used to combat "debilitating pain" following multiple back surgeries during his NFL career.
Ryan Leaf, a former NFL quarterback who has been very open about being a recovering addict after a decade-long battle with an opiate addiction, joined The Dan Patrick Show Wednesday morning where he wished Romo wouldn't have referenced back pain in his statement.
"I used to think football was the problem. No, it's a me problem. Football was never the problem; football gave me everything. I had to figure it out," Leaf told Patrick. "It's why, with the Tony Romo statement we just saw, I thought it was a very good statement; I didn't need the part about having 'debilitating back pain.' Take that whole paragraph out. You don't need any of that. You chose to do this, and it's cost you this, and you're going to admit to it, and you're going to find a way to get better."
"I was reading it with my wife yesterday," Leaf continued of Romo's statement. "And I was just like, 'Oh no.' You don't have to say that part. Everybody's had surgeries. Everybody's going through debilitating pain. I played on a golf tour with him; he was always out there on a golf tour playing. If you're in such pain, why are you out there playing golf all the time? That's not helping things."
#statement #back #going
After pleading no contest to a civil offense of operating while intoxicated in Wisconsin, Romo put out a statement admitting his "over-reliance on alcohol" while taking full responsibility for his actions before teasing his return to CBS, a return the network has not commented on as their lead NFL ****** yst remains on indefinite leave. But Romo also attributed his "over-reliance on alcohol" to his attempt at getting off a dependence on paid medication used to combat "debilitating pain" following multiple back surgeries during his NFL career.
Ryan Leaf, a former NFL quarterback who has been very open about being a recovering addict after a decade-long battle with an opiate addiction, joined The Dan Patrick Show Wednesday morning where he wished Romo wouldn't have referenced back pain in his statement.
"I used to think football was the problem. No, it's a me problem. Football was never the problem; football gave me everything. I had to figure it out," Leaf told Patrick. "It's why, with the Tony Romo statement we just saw, I thought it was a very good statement; I didn't need the part about having 'debilitating back pain.' Take that whole paragraph out. You don't need any of that. You chose to do this, and it's cost you this, and you're going to admit to it, and you're going to find a way to get better."
"I was reading it with my wife yesterday," Leaf continued of Romo's statement. "And I was just like, 'Oh no.' You don't have to say that part. Everybody's had surgeries. Everybody's going through debilitating pain. I played on a golf tour with him; he was always out there on a golf tour playing. If you're in such pain, why are you out there playing golf all the time? That's not helping things."
#statement #back #going
2 months ago
Joe Amabile paid a heartfelt tribute to his wife, Serena Pitt, on their anniversary as he continues to recover from brain tumor surgery. The former Bachelor in Paradise star praised his wife for supporting him through both the good and the difficult moments.
Joe, who became known as Grocery Store Joe during Season 14 of The Bachelorette, marked their three-year anniversary with a special post on September 2. The 40-year-old wrote on Instagram that Pitt is "the most beautiful, caring, perfect" person. "These past few months have been pretty tough, to say the least. You have been there with me every single step of the way, taking in all the good and the bad news. You cried alone in our bedroom because you didn't want to bring me down," the Dancing With the Stars alum expressed.
Continuing his post, Joe praised Serena for standing by him throughout his recovery. He said she took care of everything from cooking and cleaning to attending his doctor's appointments. She also managed his medications and woke up with him in the middle of the night. Joe said he felt incredibly lucky to have Serena as his wife, partner, and best friend. He ended the heartfelt message by telling her he loved her "forever and always."
Joe and Serena got engaged on Bachelor in Paradise season 7 in 2021. They first tied the knot at a New York City courthouse on October 27, 2022. They held a second, larger wedding celebration with loved ones in Charleston on September 2, 2023.
The former reality star first revealed the diagnosis on July 13 in an Instagram video. He said a full-body MRI scan through Prenuvo led doctors to discover an early-stage glioma. He explained that he later underwent a brain MRI. The scan showed a blueberry-sized lesion in his brain that appeared to be a glioma, which is a type of tumor.
#wife #brain #season #heartfelt
Joe, who became known as Grocery Store Joe during Season 14 of The Bachelorette, marked their three-year anniversary with a special post on September 2. The 40-year-old wrote on Instagram that Pitt is "the most beautiful, caring, perfect" person. "These past few months have been pretty tough, to say the least. You have been there with me every single step of the way, taking in all the good and the bad news. You cried alone in our bedroom because you didn't want to bring me down," the Dancing With the Stars alum expressed.
Continuing his post, Joe praised Serena for standing by him throughout his recovery. He said she took care of everything from cooking and cleaning to attending his doctor's appointments. She also managed his medications and woke up with him in the middle of the night. Joe said he felt incredibly lucky to have Serena as his wife, partner, and best friend. He ended the heartfelt message by telling her he loved her "forever and always."
Joe and Serena got engaged on Bachelor in Paradise season 7 in 2021. They first tied the knot at a New York City courthouse on October 27, 2022. They held a second, larger wedding celebration with loved ones in Charleston on September 2, 2023.
The former reality star first revealed the diagnosis on July 13 in an Instagram video. He said a full-body MRI scan through Prenuvo led doctors to discover an early-stage glioma. He explained that he later underwent a brain MRI. The scan showed a blueberry-sized lesion in his brain that appeared to be a glioma, which is a type of tumor.
#wife #brain #season #heartfelt
